Reporting owner · CIK 0001931825

Column Group Opportunity III, LP

Visual SEC Form 4 history across 3 companies, 23 transactions and 4 filings.

10%Eikon Therapeutics, Inc.
Open-market mix
Latest filingSep 08, 2026, 08:33 PM
Filings4Form 4 records
Buying—9 purchases
Selling$00 sales
Net value$0Buys minus sells
Companies37 securities
Most recentSep 03, 2026buy

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-53Mar 252Jan 263Feb 261Sep 26

Net value flow

Buys minus sells

Mar 25
—
Jan 26
$300.3K
Feb 26
$38.1M
Sep 26
$1M

Transaction texture

Ownership and ticket size

Average P/S size—
Median P/S size—
Direct0
Indirect23
Sep 03, 2026buy

Filing-only signals

Deterministic matches in this insider's history

Cluster Buypattern8Derivative Transactionfiling-context9Large Buysize3Large Holdings Increaseholdings11Repeat Buyerpattern510% Owner Buyrole8

Latest Form 4 facts

Quick context from source filings

Latest transaction

buy at Eikon Therapeutics, Inc. on Sep 03, 2026 valued at $1,031,045.

Review SEC filing
Latest buy

buy at Eikon Therapeutics, Inc. on Sep 03, 2026 valued at $1,031,045.

Review SEC filing
Latest sale

No open-market insider sale is available.

Associated companies

Visual map of known reporting history

EIKNEikon Therapeutics, Inc.18 transactions · latest Sep 08, 2026, 08:33 PMSRZNSurrozen, Inc./DE2 transactions · latest Jan 08, 2026, 10:23 PMTNYATenaya Therapeutics, Inc.3 transactions · latest Mar 08, 2025, 12:14 AM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
EIKNColumn Group Opportunity III, LP
10%
buy89.2k$103MP
Cluster Buy Large Buy Large Holdings Increase+1
0.0%09/0809/03
EIKNColumn Group Opportunity III, LP
10%
C5.13M—C
Derivative Transaction
−26.9%02/1002/06
EIKNColumn Group Opportunity III, LP
10%
C28.2k—C
Derivative Transaction
−26.9%02/1002/06
EIKNColumn Group Opportunity III, LP
10%
C827k—C
Derivative Transaction
−26.9%02/1002/06
EIKNColumn Group Opportunity III, LP
10%
C357k—C
Derivative Transaction
−26.9%02/1002/06
EIKNColumn Group Opportunity III, LP
10%
C10.4M—C
Derivative Transaction
−26.9%02/1002/06
EIKNColumn Group Opportunity III, LP
10%
C330k—C
Derivative Transaction
−26.9%02/1002/06
EIKNColumn Group Opportunity III, LP
10%
C9.67M—C
Derivative Transaction
−26.9%02/1002/06
EIKNColumn Group Opportunity III, LP
10%
buy630k$1.13BP
Cluster Buy Large Buy Large Holdings Increase+2
−26.9%02/1002/06
EIKNColumn Group Opportunity III, LP
10%
buy49.5k$89.2MP
Cluster Buy Large Holdings Increase Repeat Buyer+1
−26.9%02/1002/06

Column Group Opportunity III, LP Insider Activity FAQ

SEC Form 4 context

Who is Column Group Opportunity III, LP?

Column Group Opportunity III, LP is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001931825.

Which companies has Column Group Opportunity III, LP reported transactions for?

Eikon Therapeutics, Inc., Surrozen, Inc./DE, Tenaya Therapeutics, Inc.

When was Column Group Opportunity III, LP's latest insider buy?

buy at Eikon Therapeutics, Inc. on Sep 03, 2026 valued at $1,031,045.

When was Column Group Opportunity III, LP's latest insider sale?

No open-market insider sale is available for this period.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.